More and more people are being diagnosed with cancer. This is of concern to the pharmaceutical companies as they are now under pressure to produce safe and effective treatments. Seattle Genetics has been on the forefront in the fight against cancer.
Seattle Genetics is a company that develops antibody-drug conjugates for the treatment of cancer. Under the leadership of Dr. Clay Siegall, this company developed ADCETRIS (brentuximab vedotin), the first successful antibody-based cancer drug. Adcetris has earned $226 million in sales, both in the United States and Canada.
The success of Adcetris has led Seattle Genetics to embark on an ambitious program to develop 12 more drugs. One of these drugs, 33A, is currently at the phase three stage of clinical trials. If successful, 33A will be used in the treatment of myeloid leukemia. The other drugs undergoing trials include one for bladder cancer and two for breast cancer. Seattle Genetics is determined to satisfy the unmet needs of cancer patients.
In addition to the development of more drugs, Seattle Genetics also plans to hire 100 more employees in the United States and 20 in Switzerland. These employees will be absorbed in the operations department of the company. On average, Seattle Genetics hires 100 new employees every year.
The success of this company can largely be attributed to Dr. Clay Siegall. Dr. Siegall is an authority on targeted cancer therapies. He co-founded Seattle Genetics in 1998 and is currently the President, Chief Executive Officer and Chairman of the Board. He has guided the biotechnology company to market leadership in the use of antibody-drug conjugates (ADC) for the treatment of cancer.
Seattle Genetics has strategic licenses with several companies concerning its ADC technology. These include Genentech, Pfizer, and GlaxoSmithKline. To date, these partnerships have generated $300million for the biotech company.
Dr. Siegall has also been instrumental in securing financing for Seattle Genetics. He was behind the company’s Initial Public Offering in 2001. Since then, he has gone on to secure public and private funding worth over $675 million for the company.
Having Dr. Clay Siegall at the helm of Seattle Genetics has made a significant impact on cancer research. The promise of 12 new cancer drugs has also given hope to those who are suffering from cancer.